Aller au contenu principal
2025 article

Contemporary Insights and Emerging Paradigms in Sedation andAnalgesia Management for Ventilated Newborns

0Citations signalées, ce qui n’est pas une note de qualité
5Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : it. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Pain management in the first 1000 days of life is crucial for neurodevelopmental outcomes and the quality of life in extremely preterm newborns, who often undergo mechanical ventilation. The use of drugs like midazolam in neonatal care offers advantages such as sedation and muscle relaxation, but can also lead to potential adverse effects. Morphine, a common opioid analgesic, is used in neonatal care for its dual analgesic and sedative properties. Uncertainties regarding short-term pulmonary outcomes and concerns about neurological effects in preterm infants remain. Fentanyl, a synthetic opioid, is a first-line drug for rapid analgesia in various clinical scenarios. Adrenergic agonists and antioxidant substances, dexmedetomidine and melatonin, have shown the potential to be the first analgesic compounds suitable for both clinical trials and clinical use. Dexmedetomidine, an adrenergic agonist, stands out for its opioid-sparing effects and neuroprotective properties. Its efficacy in reducing cumulative morphine administration and supporting mechanical ventilation in certain conditions has been demonstrated. Melatonin has emerged as a neurohormone with potential analgesic properties, and various studies indicate its benefits in reducing pain-related oxidative stress and inflammation. In this educational review, we analyze and discuss pain assessment and management in patients subjected to mechanical ventilation, with a focus on pharmacological management during neonatal intubation, navigating the complexities of balancing effective analgesia and sedation while considering potential risks and outcomes in extremely preterm newborns. The positive effects of new drugs such as melatonin and dexmedetomidine on mechanically ventilated newborns mainly consist of improvements in pain management and amelioration of pulmonary function.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Contemporary Insights and Emerging Paradigms in Sedation andAnalgesia Management for Ventilated Newborns
Date Crossref
05/08/2025
Éditeur
Bentham Science Publishers Ltd.
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Neonatal Respiratory Health ResearchAnesthesia and Neurotoxicity ResearchAnesthesia and Sedative Agents

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.